Paul F Pollack - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Paul F Pollack

Showing results (11-20 of 20) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 20 results.

Drug Safety|March 1, 2003

Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infectionThierry Lacaze-Masmonteil, Juergen Seidenberg, Ian Mitchell, et al.

Journal of the American College of Nutrition|April 15, 2014

Milk protein-based infant formula containing rice starch and low lactose reduces common regurgitation in healthy term infants: a randomized, blinded, and prospective trialJohn B Lasekan, Hawley K Linke, Jeffery S Oliver, et al.

The American Journal of Gastroenterology|October 16, 2008

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trialEdward V Loftus, Brian G Feagan, Jean-Frédéric Colombel, et al.

Gastroenterology|December 24, 2013

Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's diseaseMark T Osterman, William J Sandborn, Jean-Frederic Colombel, et al.

Gastroenterology|January 24, 2007

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trialJean-Frédéric Colombel, William J Sandborn, Paul Rutgeerts, et al.

Annals of Internal Medicine|May 2, 2007

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trialWilliam J Sandborn, Paul Rutgeerts, Robert Enns, et al.

The American Journal of Gastroenterology|April 9, 2009

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trialJean-Frédéric Colombel, William J Sandborn, Paul Rutgeerts, et al.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 17, 2013

Adalimumab induces deep remission in patients with Crohn's diseaseJean-Frédéric Colombel, Paul J Rutgeerts, William J Sandborn, et al.

Gastroenterology|February 14, 2012

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trialPaul Rutgeerts, Gert Van Assche, William J Sandborn, et al.

Gastroenterology|November 8, 2021

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's DiseaseBruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, et al.

Pageof 2

Search research articles

Showing results (11-20 of 20) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 20 results.

Drug Safety|March 1, 2003

Journal of the American College of Nutrition|April 15, 2014

The American Journal of Gastroenterology|October 16, 2008

Gastroenterology|December 24, 2013

Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's diseaseMark T Osterman, William J Sandborn, Jean-Frederic Colombel, et al.

Gastroenterology|January 24, 2007

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trialJean-Frédéric Colombel, William J Sandborn, Paul Rutgeerts, et al.

Annals of Internal Medicine|May 2, 2007

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trialWilliam J Sandborn, Paul Rutgeerts, Robert Enns, et al.

The American Journal of Gastroenterology|April 9, 2009

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trialJean-Frédéric Colombel, William J Sandborn, Paul Rutgeerts, et al.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 17, 2013

Adalimumab induces deep remission in patients with Crohn's diseaseJean-Frédéric Colombel, Paul J Rutgeerts, William J Sandborn, et al.

Gastroenterology|February 14, 2012

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trialPaul Rutgeerts, Gert Van Assche, William J Sandborn, et al.

Gastroenterology|November 8, 2021

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's DiseaseBruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, et al.

Pageof 2